TUSTIN, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient ...
The expansion of LENTIVERSE™ platform introduces "One Lentiviral Vector Platform, Two Paths to Advance Cures," aligning scientific rigor with transparent economics and global accessibility.
Kirkland-based Vector Development Co. recently announced plans to build a $9.5M, 78K SF distribution center in Tacoma. The facility will be leased to one or more distribution, warehouse or ...
The global viral vector development market size is poised for remarkable growth, with a projected valuation of US$ 730.7 Million by the end of 2023 and an anticipated expansion at a Compound Annual ...
Plasmids are essential for the development of viral vectors used to manufacture novel gene therapies and viral vaccines. Aldevron is supporting the innovation of drug developers in this space by ...
Over the evaluation period from 2023 to 2033, the global viral vector development market is predicted to grow at a remarkable CAGR of 18.7%. By the end of 2023, the global market is anticipated to be ...
The dynamic landscape of molecular biology has bolstered gene-therapy endeavors, underscoring their true therapeutic potential in recent years. Investigators have come to realize that gene therapy is ...
Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first commercial viral vector Contract Development and Manufacturing Organisation (CDMO), today announces that it has entered into a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results